# Dihexa Peptide

> Dihexa is an angiotensin IV-derived molecule that targets hepatocyte growth factor signaling, synapse formation, and neurotrophic pathways.

Canonical: https://pepflow.app/peptides/dihexa/

The Fragile Nootropic

Dihexa is a small angiotensin IV-derived molecule discussed in peptide markets because of nootropic and neurotrophic claims. It is not a conventional short peptide protocol with a clinical-use pathway.

Brain health  Neuroaging biology

Tier E

Evidence Limited

Safety Limited Data

FDA status Not Approved

Last reviewed August 11, 2026 25 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is Dihexa?

Dihexa is a small angiotensin IV-derived molecule discussed in peptide markets because of nootropic and neurotrophic claims. It is not a conventional short peptide protocol with a clinical-use pathway.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>)

The key evidence issue is credibility. A prominent HGF/c-Met mechanism paper tied to Dihexa was retracted, and the related prodrug fosgonimeton has not produced a clean disease-modifying win in Alzheimer disease development.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>)

Those facts do not prove Dihexa has no biology, but they sharply lower confidence in broad cognitive-enhancement claims.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>)

## What Dihexa is investigated for

Dihexa evidence is grouped by practical use case and oral route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### Cognitive enhancement Oral 24% Limited

Cognitive enhancement remains a preclinical signal and needs retraction-aware, replication-focused framing.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/40312093/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/23055539/>)

#### Human evidence

No controlled human Dihexa cognition trial is established in the cited literature.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/40312093/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/23055539/>)

#### Animal / mechanistic evidence

Angiotensin IV-derived peptide work supports procognitive and synaptogenic effects, but the HGF/c-Met mechanism literature now includes formal retractions.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/40312093/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/23055539/>)

### ### Memory improvement Oral 23% Limited

Memory improvement is a separate animal-model signal, not a proven human memory enhancer.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/34827486/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/23055539/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/40312093/>)

#### Human evidence

No human Dihexa study establishes memory improvement.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/34827486/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/23055539/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>)

#### Animal / mechanistic evidence

APP/PS1 mouse work reported cognitive and memory rescue signals with PI3K/AKT pathway involvement, while earlier AngIV-analog work supports a procognitive rationale.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/34827486/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/23055539/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/40312093/>)

### ### Alzheimer and neurodegenerative cognition Oral 22% Limited

Neurodegenerative cognition remains a preclinical development signal, not a patient-ready use.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/34827486/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/38868475/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/40312093/>)

#### Human evidence

Related HGF/MET clinical-development literature does not establish Dihexa itself as an Alzheimer treatment.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/34827486/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/38868475/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/40312093/>)

#### Animal / mechanistic evidence

APP/PS1 mouse data and development-stage reviews position Dihexa-like HGF/MET modulation as a neurodegeneration hypothesis rather than clinical validation.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/34827486/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/38868475/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/40312093/>)

## Evidence snapshot

### Overall confidence

Limited

28%

Dihexa has no direct human outcome base, and part of the proposed mechanism has retraction history. Alzheimer and nootropic uses remain unproven signals.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

12%

### Human evidence

Insufficient

Related fosgonimeton development provides background for the pathway, but it is not direct Dihexa efficacy evidence. No controlled human Dihexa cognition trial establishes benefit.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>)

20%

### Animal / preclinical

Limited

The proposed neurotrophic pathway remains scientifically interesting but unsettled. Retraction history lowers confidence in the preclinical base.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>)

28%

### Mechanism support

Limited

Dihexa has been described as an angiotensin IV analog with proposed HGF/c-Met pathway effects. The proposed benefit is synapse-support biology, but translation has not been shown in humans.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>)

## Forms & administration

Dihexa is tracked as an oral research-market compound. Dihexa capsule-style use is separate from fosgonimeton and other hepatocyte-growth-factor-pathway clinical-development drugs.[\[11\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Dihexa%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>)

Oral

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

Common oral protocols use 10-20 mg per day.[\[11\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Dihexa%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>)

### Frequency

Usually taken once daily.[\[11\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Dihexa%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>)

### Timing Considerations

Morning is the usual timing.[\[11\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Dihexa%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>)

### Cycle Length

Common cycles run 4-8 weeks.[\[11\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Dihexa%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>)

[Full Dihexa dosage guide](<https://pepflow.app/peptides/dihexa/dosage/>)

## What to expect

### First 1-2 weeks

Oral Dihexa use may feel like changes in focus, mental stamina, task initiation, or motivation during ordinary work and study routines.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>) [\[11\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Dihexa%22&limit=1>)

### Weeks 4-8

Oral cognition-oriented effects may appear as steadier task consistency, memory routines, mood, or sleep patterns.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>) [\[11\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Dihexa%22&limit=1>)

### After stopping

Perceived focus, motivation, or cognitive stamina may drift back toward baseline after oral Dihexa exposure ends.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>) [\[11\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Dihexa%22&limit=1>)

## Safety profile

Dihexa safety centers on neuroactive effects, product identity, and sparse direct human safety data.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>)

### Cautions

- Evidence quality[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>)
- Neuroactive context[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>)
- Product quality[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>)

### What we don't know

Long-term human neurologic safety, interactions, reproductive safety, and product consistency remain unclear.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>)

## Who Dihexa is not for

Route-specific avoid and medical-review notes:

- **Pregnancy or breastfeeding**

  Pregnancy or breastfeeding warrants medical review or avoidance for Dihexa.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>)
- **Active neurologic instability**

  Active neurologic instability warrants medical review or avoidance for Dihexa.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>)
- **Cancer history without clinician review**

  Cancer history without clinician review warrants medical review or avoidance for Dihexa.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>)

## Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

### Theoretical interactions

- **Stimulants / wakefulness drugs**

  Amphetamines, methylphenidate, modafinil, or high-caffeine nootropics can compound insomnia, anxiety, or overstimulation; this is a theoretical neuroactive caution.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>)
- **Sedatives / alcohol**

  Alcohol, benzodiazepines, sleep drugs, or sedating supplements can obscure cognition, coordination, and next-day effects; this is a theoretical neuroactive caution.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>)
- **Psychiatric / seizure-threshold drugs**

  Antidepressants, antipsychotics, or seizure-threshold-active drugs can make mood or neurologic changes harder to attribute; this is a theoretical neuroactive caution.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>)

## Regulatory status

### United States

In the U.S. as of 2026-06-21, Dihexa is not FDA-approved for the reviewed oral route. FDA compounding safety-risk materials flag this substance or close naming variant, so the 503A row should be read as a safety-risk bucket, not approval.[\[17\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[11\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Dihexa%22&limit=1>) [\[12\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Oral | Not Approved · Dihexa is not FDA-approved as an oral drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval.[\[11\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Dihexa%22&limit=1>) [\[12\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>) | Flagged · FDA safety-risk materials flag dihexa acetate because human exposure data and core human safety information are missing. This is a 503A compounding safety-risk bucket, not FDA drug approval.[\[17\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[11\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Dihexa%22&limit=1>) [\[12\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>) |

### Oral

FDA drug approval

Not Approved

Dihexa is not FDA-approved as an oral drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval.[\[11\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Dihexa%22&limit=1>) [\[12\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

503A compounding

Flagged

FDA safety-risk materials flag dihexa acetate because human exposure data and core human safety information are missing. This is a 503A compounding safety-risk bucket, not FDA drug approval.[\[17\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[11\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Dihexa%22&limit=1>) [\[12\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

### International

EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. Research-market, supplement, or compounded availability should not be treated as therapeutic approval in those markets.[\[18\]](<https://www.ema.europa.eu/en/medicines>) [\[19\]](<https://products.mhra.gov.uk/>) [\[20\]](<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>) [\[21\]](<https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg>)

### Sports & competition

WADA S0 can apply to non-approved pharmacological substances that are not otherwise named. Tested athletes should not treat Dihexa oral route as athlete-cleared without sport-specific review.[\[13\]](<https://ita.sport/resource/wada-2026-prohibited-list/>) [\[11\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Dihexa%22&limit=1>) [\[12\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

## How it works

Dihexa has been described as an angiotensin IV analog with proposed HGF/c-Met effects, meaning a pathway once framed around synapse formation and neuronal support. That biology is attractive for cognition claims, but it is no longer a clean foundation.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>)

The central mechanism paper was retracted, and the related fosgonimeton development story has not produced a settled disease-modifying Alzheimer outcome. Oral research-market exposure also leaves blood-brain delivery, dose, and safety questions separate from the original pathway hypothesis. Independent replication would be needed before the mechanism can anchor user-facing benefit claims.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>)

## Research gaps & open questions

What the current literature has not yet settled about Dihexa:

01

Independent laboratories need to confirm Dihexa's proposed mechanism, especially because a key supporting paper was retracted.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>)

02

No human studies have established how Dihexa is absorbed, distributed, or cleared, or whether it improves memory or thinking.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>)

03

Long-term studies need to examine effects on the brain and whether Dihexa's growth-signaling mechanism could affect cancer risk.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>)

## Common questions

### Is Dihexa a peptide?

No. Dihexa is better described as an angiotensin IV-derived small-molecule analog; oral exposure and cognition evidence remain separate questions.[\[11\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Dihexa%22&limit=1>) [\[12\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>)

### Was a key Dihexa paper retracted?

Yes. The retraction weakens confidence in the HGF/c-Met mechanism claim that many Dihexa cognition claims rely on.[\[11\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Dihexa%22&limit=1>) [\[12\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>)

### Is Dihexa proven for memory?

No. Controlled human Dihexa trials do not establish memory or Alzheimer benefit; oral exposure and HGF/c-Met mechanism claims remain unresolved.[\[11\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Dihexa%22&limit=1>) [\[12\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>)

## Myths & misconceptions

### Myth

The retraction does not matter for users.

### Reality

It matters because the retracted mechanism was central to many nootropic claims.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>)

### Myth

Fosgonimeton proves Dihexa works.

### Reality

A related prodrug program does not prove Dihexa products improve cognition.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>)

## History & discovery

Dihexa became visible through angiotensin IV analog research that proposed HGF/c-Met synaptogenic signaling as a cognition route. Its history later changed because evidence-quality and translation questions became central.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>)

Early papers framed Dihexa and related analogs as small molecules for Alzheimer and Parkinson disease concepts. That positioned Dihexa around synapse-support biology before any practical human protocol existed.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>)

A retraction tied to the HGF/Met analog program and mixed fosgonimeton development results weakened the original mechanism story. The history now argues for caution, replication, and human outcome evidence.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25187433/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40312092/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41393340/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25455861/>)

## Published research 25 citations

- [\[1\] **The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system.** J Pharmacol Exp Ther, 2014 Nov. review.](<https://pubmed.ncbi.nlm.nih.gov/25187433/>)
- [\[2\] **Retraction notice to "Development of Angiotensin IV Analogs as Hepatocyte Growth Factor/Met Modifiers" \[J Pharmacol Exp Ther 340 (2012) 539-548\].** J Pharmacol Exp Ther, 2025 Apr. review.](<https://pubmed.ncbi.nlm.nih.gov/40312092/>)
- [\[3\] **Retraction notice to "The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System" \[J Pharmacol Exp Ther 351 (2014) 390-402\].** J Pharmacol Exp Ther, 2025 Apr. review.](<https://pubmed.ncbi.nlm.nih.gov/40312093/>)
- [\[4\] **Fosgonimeton in mild-to-moderate Alzheimer's disease.** J Alzheimers Dis Rep, 2025 Jan-Dec. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/41393340/>)
- [\[5\] **The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases.** Prog Neurobiol, 2015 Feb. review.](<https://pubmed.ncbi.nlm.nih.gov/25455861/>)
- [\[6\] **AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway.** Brain Sci, 2021 Nov 11. animal.](<https://pubmed.ncbi.nlm.nih.gov/34827486/>)
- [\[7\] **Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents.** J Pharmacol Exp Ther, 2013 Jan. animal.](<https://pubmed.ncbi.nlm.nih.gov/23055539/>)
- [\[8\] **Cognitive Impairment in Parkinson's Disease: An Updated Overview Focusing on Emerging Pharmaceutical Treatment Approaches.** Medicina (Kaunas), 2023 Oct 1. review.](<https://pubmed.ncbi.nlm.nih.gov/37893474/>)
- [\[9\] **Beyond lecanemab: Examining Phase III potential in Alzheimer's therapeutics.** PCN Rep, 2024 Mar. review.](<https://pubmed.ncbi.nlm.nih.gov/38868475/>)
- [\[10\] **Stem cell, Granulocyte-Colony Stimulating Factor and/or Dihexa to promote limb function recovery in a rat sciatic nerve damage-repair model: Experimental animal studies.** Ann Med Surg (Lond), 2021 Nov. animal.](<https://pubmed.ncbi.nlm.nih.gov/34703584/>)
- [\[11\] **Drugs@FDA/openFDA query for Dihexa** U.S. Food and Drug Administration. database query.](<https://api.fda.gov/drug/drugsfda.json?search=%22Dihexa%22&limit=1>)
- [\[12\] **Compounding and the FDA: Questions and Answers** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)
- [\[13\] **The 2026 List of Prohibited Substances and Methods** World Anti-Doping Agency. regulatory.](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- [\[14\] **FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)
- [\[15\] **Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act** U.S. Food and Drug Administration, 2026-05-14. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>)
- [\[16\] **Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C Act** U.S. Food and Drug Administration, 2025-01-07. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)
- [\[17\] **Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks** U.S. Food and Drug Administration, 2026-04-22. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- [\[18\] **European Medicines Agency medicines search** European Medicines Agency. official guidance.](<https://www.ema.europa.eu/en/medicines>)
- [\[19\] **MHRA Products search** Medicines and Healthcare products Regulatory Agency. official guidance.](<https://products.mhra.gov.uk/>)
- [\[20\] **Drug Product Database: Access the database** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>)
- [\[21\] **Searching the Australian Register of Therapeutic Goods** Therapeutic Goods Administration. official guidance.](<https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg>)
- [\[22\] **Cosmetic Products Regulation** European Commission. official guidance.](<https://single-market-economy.ec.europa.eu/sectors/cosmetics/legislation_en>)
- [\[23\] **Making cosmetic products available to consumers in Great Britain** UK Office for Product Safety and Standards. official guidance.](<https://www.gov.uk/guidance/making-cosmetic-products-available-to-consumers-in-great-britain>)
- [\[24\] **Cosmetics regulatory information** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/consumer-product-safety/cosmetics/regulatory-information.html>)
- [\[25\] **Cosmetics and soap** Australian Industrial Chemicals Introduction Scheme. official guidance.](<https://www.industrialchemicals.gov.au/cosmetics-and-soap>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

Neuroactive peptide

**Tier**

E

**Evidence**

28% Limited

**Safety**

Limited Data

**FDA status**

Not Approved

**Oral 503A**

Flagged

**Citations**

[25 citations](<https://pepflow.app/peptides/dihexa/#published-research>)

**Updated**

August 11, 2026

### Potential benefits

- Cognitive enhancement
- Memory improvement
- Alzheimer and neurodegenerative cognition

### Also known as

- N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
- Angiotensin IV analog
- PNB-0408-related analog

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [Dihexa dosage guide](<https://pepflow.app/peptides/dihexa/dosage/>)
- [PepFlow Library Statistics (2026) · 65 Profiles](<https://pepflow.app/research/peptide-library/>)
